You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧賽圖-B(02315.HK):就具有同類首創潛力的B7H3/PTK7拓撲異構酶抑制劑有效載荷雙特異性ADC項目與IDEAYA達成選擇權及授權協議
格隆匯 07-31 17:32

格隆匯7月31日丨百奧賽圖-B(02315.HK)發佈公吿,公司今日與IDEAYA Biosciences(其普通股於納斯達克全球精選市場上市,股份代號為“IDYA”、“IDEAYA”),已訂立一項選擇權及授權協議。該協議將授予IDEAYA一項選擇權來獲得百奧賽圖有潛力的同類首創B7H3/PTK7拓撲異構酶抑制劑有效載荷BsADC項目的全球獨家許可。根據該協議的條款,百奧賽圖將獲得一筆首付款,如果IDEAYA行使了選擇權,百奧賽圖有權獲得選擇權行使費、開發和監管里程碑付款、商業化里程碑付款以及個位數淨銷售額分成。潛在交易總額達4.065億美元,其中包括1億美元的臨牀開發和監管里程碑付款。

已發現B7H3或PTK7在多種實體瘤類型中共同表達,包括肺癌、結直腸癌及頭頸癌的兩位數患病率。根據臨牀前數據,有潛力的同類首創B7H3/PTK7拓撲異構酶抑制劑有效載荷BsADC項目有可能作為單藥療法藥物進行開發,也有可能與 IDEAYA管線中基於針對DNA損傷修復(DDR)療法的多個項目(包括PARG抑制劑 IDE161)進行聯合使用。B7H3/PTK7拓撲異構酶抑制劑有效載荷BsADC項目的開發候選藥物提名計劃在2024年下半年完成。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account